Toggle navigation
About
Mission
Team
Careers
Our Science
Adaptive Stress
Innate and Adaptive Immunity
QuAD3 Platform
Programs
Pipeline
Stress Modulator
Platform
Innate and Adaptive
Immune Modulator
Patients & Caregivers
News & Publications
Contact
About
Mission
Team
Careers
Our Science
Adaptive Stress
Innate and Adaptive Immunity
QuAD3 Platform
Programs
Pipeline
Stress Modulator
Platform
Innate and Adaptive
Immune Modulator
Patients & Caregivers
News & Publications
Contact
News & Publications
News & Publications
News & Publications
News
Presentations &
Publications
News
Presentations &
Publications
News
Presentations & Publications
05.26.22 - publication
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
Read More
05.24.22 - news
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
Read More
05.13.22 - news
HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022
Read More
04.28.22 - news
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer
Read More
03.03.22 - news
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment
Read More
02.24.22 - news
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
Read More
12.23.21 - publication
GCN2 kinase activation by ATP-competitive kinase inhibitors
Read More
12.14.21 - news
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Patients with Metastatic Breast Cancer
Read More
12.09.21 - news
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021
Read More
12.07.21 - news
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium
Read More
10.26.21 - publication
Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort
Read More
10.26.21 - news
HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19
Read More
09.30.21 - news
HiberCell Appoints Jonathan Lanfear as COO
Read More
09.24.21 - publication
Targeting the Integrated Stress Response in Cancer Therapy
Read More
09.08.21 - news
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
Read More
08.16.21 - news
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.
Read More
07.30.21 - publication
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
Read More
07.30.21 - publication
PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells
Read More
06.29.21 - news
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
Read More
06.10.21 - news
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
Read More
05.19.21 - news
HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital
Read More
04.28.21 - publication
Quantum processor-inspired machine learning in the biomedical sciences
Read More
01.21.21 - news
HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.
Read More
01.17.21 - publication
Activation of the Integrated Stress Response overcomes multidrug resistance in FBXW7-deficient cells
Read More
01.13.21 - news
HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization
Read More
12.02.20 - news
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer
Read More
11.05.20 - publication
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Read More
07.07.20 - news
HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program
Read More
04.02.20 - publication
Smooth Muscle Cell Reprogramming in Aortic Aneurysms
Read More
04.01.20 - publication
A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit
Read More
03.13.20 - publication
Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia
Read More
02.10.20 - publication
Chronic mTOR activation induces a degradative smooth muscle cell phenotype
Read More
12.04.19 - news
Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis
Read More
12.01.19 - publication
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
Read More
12.01.19 - publication
Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
Read More
11.01.19 - publication
Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection
Read More
11.01.19 - publication
A MYC-GCN2-eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer
Read More
11.01.19 - publication
Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects
Read More
11.01.19 - publication
Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab
Read More
08.26.19 - publication
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis
Read More
08.06.19 - news
HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors
Read More
06.13.19 - publication
Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium
Read More
05.01.19 - publication
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers
Read More
02.07.19 - news
STAT – New York biotech debuts, targeting dormant metastatic cancer cells
Read More
02.07.19 - news
FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis
Read More
02.07.19 - news
Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis
Read More
02.07.19 - news
HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics
Read More
01.14.19 - publication
Enhancing Retrosynthetic Reaction Prediction with Deep Learning Using Multiscale Reaction Classification
Read More
12.18.18 - publication
ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma
Read More
10.16.18 - news
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Read More
09.28.18 - news
How dormant cancer persists and reawakens
Read More
06.01.18 - publication
Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases
Read More
05.01.18 - publication
Development of a stress response therapy targeting aggressive prostate cancer
Read More
04.01.18 - publication
Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma
Read More
04.01.18 - publication
Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo
Read More
04.01.18 - publication
Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing
Read More
03.01.18 - publication
The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma
Read More
02.02.18 - publication
Aging and neurodegeneration are associated with increased mutations in single human neurons
Read More
01.01.18 - publication
Role of HIF-1 in Cancer Progression: Novel Insights. A Review
Read More
12.15.17 - publication
Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification.
Read More
10.10.17 - publication
Recent Insights into the Role of Unfolded Protein Response in ER Stress in Health and Disease
Read More
05.11.17 - publication
FGF-dependent metabolic control of vascular development
Read More
12.13.16 - news
Mechanism of early dissemination and metastasis in Her2+ mammary cancer
Read More
10.02.15 - publication
Somatic mutation in single human neurons tracks developmental and transcriptional history
Read More
08.01.15 - publication
Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy
Read More
01.30.15 - news
NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes
Read More
12.04.14 - publication
Proteomic analysis and identification of cellular interactors of the giant ubiquitin ligase HERC2
Read More
04.13.14 - publication
Keeping the eIF2 alpha kinase Gcn2 in check
Read More
02.24.14 - publication
Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
Read More
05.26.22 - publication
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
Read More
05.24.22 - news
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
Read More
05.13.22 - news
HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022
Read More
04.28.22 - news
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer
Read More
03.03.22 - news
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment
Read More
02.24.22 - news
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
Read More
12.23.21 - publication
GCN2 kinase activation by ATP-competitive kinase inhibitors
Read More
12.14.21 - news
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Patients with Metastatic Breast Cancer
Read More
12.09.21 - news
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021
Read More
12.07.21 - news
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium
Read More
10.26.21 - publication
Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort
Read More
10.26.21 - news
HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19
Read More
09.30.21 - news
HiberCell Appoints Jonathan Lanfear as COO
Read More
09.24.21 - publication
Targeting the Integrated Stress Response in Cancer Therapy
Read More
09.08.21 - news
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
Read More
08.16.21 - news
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.
Read More
07.30.21 - publication
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
Read More
07.30.21 - publication
PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells
Read More
06.29.21 - news
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
Read More
06.10.21 - news
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
Read More
05.19.21 - news
HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital
Read More
04.28.21 - publication
Quantum processor-inspired machine learning in the biomedical sciences
Read More
01.21.21 - news
HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.
Read More
01.17.21 - publication
Activation of the Integrated Stress Response overcomes multidrug resistance in FBXW7-deficient cells
Read More
01.13.21 - news
HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization
Read More
12.02.20 - news
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer
Read More
11.05.20 - publication
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Read More
07.07.20 - news
HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program
Read More
04.02.20 - publication
Smooth Muscle Cell Reprogramming in Aortic Aneurysms
Read More
04.01.20 - publication
A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit
Read More
03.13.20 - publication
Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia
Read More
02.10.20 - publication
Chronic mTOR activation induces a degradative smooth muscle cell phenotype
Read More
12.04.19 - news
Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis
Read More
12.01.19 - publication
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
Read More
12.01.19 - publication
Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
Read More
11.01.19 - publication
Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection
Read More
11.01.19 - publication
A MYC-GCN2-eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer
Read More
11.01.19 - publication
Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects
Read More
11.01.19 - publication
Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab
Read More
08.26.19 - publication
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis
Read More
08.06.19 - news
HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors
Read More
06.13.19 - publication
Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium
Read More
05.01.19 - publication
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers
Read More
02.07.19 - news
STAT – New York biotech debuts, targeting dormant metastatic cancer cells
Read More
02.07.19 - news
FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis
Read More
02.07.19 - news
Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis
Read More
02.07.19 - news
HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics
Read More
01.14.19 - publication
Enhancing Retrosynthetic Reaction Prediction with Deep Learning Using Multiscale Reaction Classification
Read More
12.18.18 - publication
ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma
Read More
10.16.18 - news
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Read More
09.28.18 - news
How dormant cancer persists and reawakens
Read More
06.01.18 - publication
Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases
Read More
05.01.18 - publication
Development of a stress response therapy targeting aggressive prostate cancer
Read More
04.01.18 - publication
Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma
Read More
04.01.18 - publication
Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo
Read More
04.01.18 - publication
Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing
Read More
03.01.18 - publication
The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma
Read More
02.02.18 - publication
Aging and neurodegeneration are associated with increased mutations in single human neurons
Read More
01.01.18 - publication
Role of HIF-1 in Cancer Progression: Novel Insights. A Review
Read More
12.15.17 - publication
Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification.
Read More
10.10.17 - publication
Recent Insights into the Role of Unfolded Protein Response in ER Stress in Health and Disease
Read More
05.11.17 - publication
FGF-dependent metabolic control of vascular development
Read More
12.13.16 - news
Mechanism of early dissemination and metastasis in Her2+ mammary cancer
Read More
10.02.15 - publication
Somatic mutation in single human neurons tracks developmental and transcriptional history
Read More
08.01.15 - publication
Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy
Read More
01.30.15 - news
NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes
Read More
12.04.14 - publication
Proteomic analysis and identification of cellular interactors of the giant ubiquitin ligase HERC2
Read More
04.13.14 - publication
Keeping the eIF2 alpha kinase Gcn2 in check
Read More
02.24.14 - publication
Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
Read More
View More